Gilead Sciences: Pipeline, Products, Performance, Potential

Table of Contents

Latest Results

EXECUTIVE SUMMARY

• Introduction
• Current Financial Position
  • Company Performance
  • Business Segment Performance
  • Geographic Segment Performance
• Company Strategy
  • Mergers, Acquisitions and Divestitures
  • Key Agreements
  • Employees
• Product Performance Forecasts
• Pipeline Analysis
• Conclusions/Outlook
• Other Factors Affecting the Bottom Line

THERAPEUTIC AREA FOCUS

R&D PIPELINE

ANTI-VIRAL

• Marketed Products
  • HIV
    • Atripla
    • Truvada
    • Viread
    • Others
  • Hepatitis
    • Hepsera
• R&D Projects
  • HIV
    • GS 9137
  • Hepatitis
  • Discontinued R&D Projects
• Growth Forecast
  • HIV
  • Hepatitis

OTHER AREAS

• Marketed Products
  • AmBisome
  • Others
• R&D Projects
  • Ambrisentan
  • Aztreonam lysine
  • Darusentan
• GROWTH FORECAST

APPENDIX 1 - FINANCIAL PERFORMANCE

• Full Year Results 2006

APPENDIX 2 - KEY CORPORATE EVENTS

APPENDIX 3 - KEY AGREEMENTS

• 4AZA Bioscience
• Achillion Pharmaceuticals
• Anadys Pharmaceuticals
• Aspen Pharmacare
• Astellas Pharma
• Bristol-Myers Squibb
• Chimerix
• Dainippon Sumitomo Pharma
• Diatos
• Emory University/Royalty Pharma
• Genelabs Technologies
• GlaxoSmithKline
• International Partnership for Microbicides /CONRAD
• Japan Tobacco
• Merck & Co
• Novartis
• Roche

APPENDIX 4 - INFRASTRUCTURE

• Research and Development Facilities
• Manufacturing Facilities

APPENDIX 5 - KEY PHARMACEUTICAL SUBSIDIARIES / JOINT VENTURES

• Subsidiaries
• Joint Ventures

APPENDIX 6 - PRODUCT INDEX

Index of Tables

• Principal Operating Results
• R&D Expenditure
• Sales By Destination
• Major Products, Therapeutic Areas and Sales
• Major HIV Products, 2006
• Major Hepatitis Products, 2006
• Major Other Area Products, 2006

Index of Charts

• R&D Expenditure, 2006
• Sales By Destination
• Sales of Top Five Products (2004A-2011E)
• Top Selling Products, 2006
• Atripla Sales (2000A-2010E)
• Truvada Sales (2001A-2011E)
• Viread Sales (2001A-2011E)
• Hepsera Sales (2001A-2010E)
• GS 9137 Sales (2001A-2011E)
• HIV Product Portfolio Forecast (2006A-2011E)
• AmBisome Sales (2001A-2011E)
• Sales, Costs and Operating Income
• Profitability and Research Ratios
• R&D Expenditure and Capital Expenditure
• Current Assets, Liabilities and Ratio
• Assets, Cash and Liquidity
• Employees and Productivity